(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Dianthus Therapeutics's earnings in 2025 is -$126,345,000.On average, 17 Wall Street analysts forecast DNTH's earnings for 2025 to be -$159,344,422, with the lowest DNTH earnings forecast at -$188,242,856, and the highest DNTH earnings forecast at -$143,163,014. On average, 16 Wall Street analysts forecast DNTH's earnings for 2026 to be -$158,251,084, with the lowest DNTH earnings forecast at -$179,839,157, and the highest DNTH earnings forecast at -$135,509,645.
In 2027, DNTH is forecast to generate -$180,700,965 in earnings, with the lowest earnings forecast at -$219,756,727 and the highest earnings forecast at -$145,864,203.